pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,400 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1876Endpoints1456Fierce Biotech771BioSpace762BioPharma Dive551raps249onclive165fda recalls121
therapy area
allOncology12969Rare Disease3359Immunology3054Cardiology2860Hematology2304Pulmonology2255Vaccines
  • FDA approves Regeneron's first siRNA therapy for generalized myasthenia gravis
    The FDA has granted approval for Regeneron's siRNA drug Livsayis (cemdisiran) for adult patients with generalized myasthenia gravis who are positive for anti‑acetylcholine receptor antibodies. Thi…
    BioSpace · 3h agoApprovalPositive↗ source
  • Sanofi explores acquisition of Insmed in potential major biopharma deal
    Sanofi is reportedly evaluating a purchase of the U.S. drugmaker Insmed, according to a Bloomberg News report. The potential transaction would rank among the largest biopharma acquisitions in rece…
    Endpoints · 1h agoDealNeutral↗ source
← prev
page 1 of 216
next →
fda medwatch116
globenewswire health73
fda press62
1861
Psychiatry & CNS1235
Ophthalmology1139
Endocrinology & Metabolism809
Pain792
Nephrology787
  • FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolio
    Regeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
    Endpoints · 3h agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 4h agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 6h agoDealPositive↗ source
  • Isomorphic Labs partners with Merck on AI-driven oncology drug discovery after $5 billion funding round
    Isomorphic Labs announced a new collaboration with Merck & Co., adding the pharma giant to its AI drug discovery partners. The agreement follows Isomorphic's recent $5 billion financing and will f…
    Fierce Biotech · 9h agoDealPositive↗ source
  • AbbVie signs up to $2.5 B licensing deal with DISCO to develop solid tumor bispecific therapies
    AbbVie announced a licensing agreement with European biotech DISCO Pharmaceuticals that could be worth as much as $2.5 billion. The deal includes a $40 million upfront payment and future milestones…
    BioSpace · 11h agoDealPositive↗ source
  • AbbVie partners with Disco Pharmaceuticals on up to $2.5 billion solid tumor deal
    AbbVie announced a partnership with Disco Pharmaceuticals, a preclinical cancer biotech based in Cologne, Germany, to advance antibody‑drug conjugate and T cell engager programs targeting solid tum…
    Endpoints · 11h agoDealPositive↗ source
  • Novartis CEO says shareholders remain supportive despite recent trial setbacks
    Novartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
    Fierce Biotech · 13h agoPositive↗ source
  • Telehealth firms Hims & Hers and Noom launch prescription peptide programs after HHS rule change
    Telehealth companies Hims & Hers and Noom announced this week that they will begin prescribing peptide products to eligible patients, marking the first major consumer‑focused rollouts of such thera…
    STAT · 1h agoNeutral↗ source
  • Chinese AI lab MegaRobo secures almost $200 million in funding as Isomorphic strikes partnership with Merck
    Chinese AI and lab-automation company MegaRobo announced it has raised close to $200 million, according to a post on WeChat. The capital injection is intended to expand the firm’s artificial-intel…
    Endpoints · 1h agoDealPositive↗ source
  • Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patent
    Novartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…
    BioSpace · 1h agoNeutral↗ source
  • Oura announces acquisition of Counsel Health at HLTH conference
    Oura, known for its wearable health tracker, disclosed that it is purchasing Counsel Health, a company that provides health data services. The announcement was made during the HLTH conference, whe…
    Endpoints · 1h agoDealPositive↗ source
  • Novartis reports mid-stage eczema drug success, plans to restart autoimmune CAR-T trials and narrows sales growth outlook
    Novartis said its experimental eczema treatment achieved a positive result in a mid-stage study, marking the company's first major clinical milestone in the skin-disorder area this year. The compa…
    Endpoints · 2h agoPositive readoutNeutral↗ source
  • nChroma Bio cuts workforce by half and stops HBV cure trial
    nChroma Bio, a Boston biotech focused on epigenetic therapies, announced it is reducing its staff by roughly half. The reduction follows the decision to halt enrollment in its phase 1/2 study of C…
    Fierce Biotech · 8h agoLayoffsNegative↗ source
  • Nine California biotech firms slash at least half of their workforces amid statewide cuts
    Workforce reductions have affected more than 1,000 biopharma employees in California so far this year, with the hardest hits falling on biotech firms. Nine companies have announced plans to cut at…
    BioSpace · 13h agoLayoffsNegative↗ source
  • Actinogen’s Alzheimer’s drug Xanamem fails pivotal trial, shares plunge over 80%
    Actinogen Medical, an Australian biotech, reported that its only candidate, Xanamem (emestedastat), did not meet the primary endpoint in a Phase 2b/3 study in patients with mild to moderate Alzheim…
    BioSpace · 2h agoNegative readoutNegative↗ source
  • Eli Lilly pilots virtual clinician platform to speed Alzheimer’s diagnosis
    Eli Lilly is testing a new virtual‑clinician service aimed at accelerating the diagnosis and early care for people showing signs of Alzheimer’s disease. The approach allows individuals with memory…
    Endpoints · 4h agoPositive↗ source
  • Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune Programs
    Evaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
    Fierce Biotech · 8h agoNeutral↗ source
  • Teva R&D chief Eric Hughes resigns as company pushes innovative medicines expansion
    Teva Pharmaceutical announced that its head of research and development, Eric Hughes, M.D., Ph.D., will resign, with his departure set to occur over the next few months. Hughes joined Teva in 2022…
    Fierce Biotech · 12h agoNeutral↗ source
  • National Academies urges faster retractions and corrections to protect scientific record
    The National Academies of Sciences, Engineering, and Medicine released a report urging the scientific community to act more quickly when errors or data manipulation are identified in published rese…
    STAT · 2h agoPositive↗ source
  • FDA puts drug repurposing front-and-center, says BioSpace podcast
    In a recent episode of BioSpace’s podcast “Denatured,” host Jennifer C. Smith-Parker spoke with Daniel Tillett, chief executive of Racura Oncology, and Sten Sörensen, chief executive of Cereno Scie…
    BioSpace · 6h agoRegulatoryNeutral↗ source
  • MAHA PAC spent more on its own D.C. steakhouse events than on a key ally’s House race before midterm losses
    The political arm of Make America Healthy Again (MAHA) directed millions of dollars to its own operations, including a high‑profile dinner in Washington, D.C., rather than funneling that money to c…
    STAT · 8h agoNegative↗ source
  • Sanders says expanded Medicare plan may still pass despite Trump’s potential veto
    Senator Bernie Sanders told reporters that he is not certain a Trump veto would block an expanded Medicare for All proposal, suggesting the legislation could still move forward. The proposal appea…
    STAT · 5h agoNeutral↗ source
  • Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese data
    Erasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…
    STAT · 6h agoNeutral↗ source